Sangamo Therapeutics Stock Price and Value Analysis

Should you buy Sangamo Therapeutics stock? (NasdaqGS:SGMO). Let's see how it does in our automated value investing analysis system.

SGMO Free Cash Flow Trend

Free Cash Flow trendline for SGMO
Free Cash Flow trendline for Sangamo Therapeutics

Hmm, we can't give any reliable projection for Sangamo Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company is solid.
  • This company has fluctuating growth.
  • This company is not making money.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the SGMO Numbers

SGMO Price
(Sangamo Therapeutics stock price per share)
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Biotechnology stocks
[?] Cash Yield -2.55%
[?] Free Cash Flow Jitter 30%

Is Sangamo Therapeutics Stock on Sale?

Based on our analysis, we believe that you should not buy Sangamo Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy SGMO Stock?

Does Sangamo Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.